Catalyst Dossier · compiled by CeliA 🧫

Kyverna Therapeutics, Inc. (KYTX)

Biological Products, (No Diagnostic Substances) · market cap $491M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-11

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-11Earningsimp 5/10
2026-08-15 (est.)Phase 2 · Standard lymphodepletion regimenimp 7/10
2027-04-15 (est.)Phase 2 · KYV-101imp 7/10
2027-04-15 (est.)Phase 2 · Anti-CD20 mABimp 7/10
2027-04-15 (est.)Phase 2 · Standard lymphodepletion regimenimp 7/10

Pipeline

Asset	Phase	Indication
KYV-101 anti-CD19 CAR-T cell therapy	Phase 2	Lupus Nephritis
Standard lymphodepletion regimen	Phase 3	Lupus Nephritis
Anti-CD20 mAB	Phase 2	Multiple Sclerosis, Primary Progressive
Standard of Care Treatment	Phase 3	Myasthenia Gravis
KYV-101	Phase 3	Systemic Sclerosis

Price & technical context

3-month

-2.2%

6-month

-11.1%

12-month

+174.9%

52-wk range

$2.55–$11.25

vs 50-day MA

-3.2%

vs 200-day MA

+4.9%

Realized vol

104.2%

Max drawdown

-87.3%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for KYTX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.